Foster City, CA, and Hangzhou, China, July 26, 2022 – (ACN Newswire) – Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics’ China General Manager and will report to the Chief Executive Officer.

“We are very excited to have Jane join our team,” said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. “Jane is a drug discovery expert in a number of therapeutic areas, including oncology, with a proven track record advancing compounds from the laboratory to clinical development. With her broad experience, she will make significant contributions to our global research strategy.”

“I am pleased to join a Company dedicated to the discovery, research, and clinical development of novel agents targeting multiple oncology indications. I look forward to growing our global team to discover and advance new compounds into the clinic,” added Jane Wang, Ph.D., Chief Scientific Officer.

Dr. Wang brings over 20 years of drug discovery experience in the biopharmaceutical industry. Most recently, she served as Vice President, Medicinal Chemistry at WuXi AppTec where she worked to enhance RNA drug discovery and led multiple teams in medicinal chemistry and synthetic organic chemistry. Prior to WuXi, Dr. Wang spent 12 years on the drug discovery team at Pfizer, Inc. as a senior principal scientist, focusing on diseases in oncology, inflammation, and the central nervous system Previously, she did her postdoc at the U.S. National Institute of Health and at Schering-Plough. Dr. Wang earned a Ph.D. from the University of Maryland Baltimore County and a B.S. in Applied Chemistry from Fudan University. She is an inventor/co-inventor of over 50 patent applications and an author of over 35 publications.

About Apollomics Inc.

Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company’s product pipeline has several programs at different stages of development, including a novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.

Contact Information:

Investor Contact:

Raymond Low

VP Finance, Corporate Controller

(925) 451-0712

Raymond.Low@apollomicsinc.com

U.S. Media Contact:

Remy Bernarda

Corporate Communications

(415) 203-6386

remy.bernarda@apollomicsinc.com

China Media Contact:

Porda Havas International Finance Communications Group

Kelly Fung

General Manager

(852) 3150 6763

kelly.fung@pordahavas.com






Topic: Press release summary



Source: Apollomics, Inc.




Sectors: BioTech, Clinical Trials



http://www.acnnewswire.com


From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.









































Apollomics, Inc.
Jan 12, 2022 09: 25 HKT/SGT

Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Jan 4, 2022 10: 10 HKT/SGT

Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Nov 22, 2021 10: 40 HKT/SGT

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Oct 1, 2021 10: 00 HKT/SGT

Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
Aug 10, 2021 11: 53 HKT/SGT

Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
May 20, 2021 13: 36 HKT/SGT

APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
Mar 9, 2021 10: 35 HKT/SGT

Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
Mar 4, 2021 11: 30 HKT/SGT

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA
Feb 12, 2021 13: 00 HKT/SGT

Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
Feb 11, 2021 11: 00 HKT/SGT

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
More news >>